Ashwagandha for Perimenopause: What The Evidence Shows
Ashwagandha may help with stress and sleep, while direct perimenopause evidence comes mainly from one small trial. That distinction matters.
If your stress, sleep and hot-flash clusters all got louder together, ashwagandha looks tempting. One supplement. One daily decision. Very easy to turn a complicated symptom picture into a simple fix.
The evidence is more specific than that.
One 8-week randomized, placebo-controlled trial studied 100 perimenopausal women with climacteric symptoms. Ninety-one finished. Participants took 300 mg of ashwagandha root extract twice daily, so 600 mg per day, or placebo. The extract group improved more on the overall Menopause Rating Scale, menopause-specific quality of life and reported hot flashes.[1] That is encouraging. It is also one trial, not a settled verdict.
The U.S. National Center for Complementary and Integrative Health says the menopause evidence remains insufficient overall and notes that many ashwagandha studies are small and use different preparations.[2]
Ashwagandha for perimenopause, symptom by symptom
Hot flashes: The clearest direct menopause signal also comes from that single trial. Participants reported fewer or less intense hot flashes after eight weeks on 300 mg twice daily.[1] Still, a menopause rating scale is not the same as counting every episode for months. We do not yet know who benefits, for how long, or whether the result holds outside that trial.
Stress, anxiety and a short fuse: This is where ashwagandha has more research, but mostly in people with stress or anxiety, not specifically perimenopause. A 2024 meta-analysis of nine randomized trials found reductions in perceived stress, anxiety scores and cortisol. Extracts and doses varied, and the authors called for better trials and longer safety data.[3] So: plausible for the stress piece, not proof that a new anxiety symptom is menopausal. If anxiety is persistent, severe or sudden, get it checked rather than self-diagnosing it as perimenopause. Our mood supplement guide separates those questions too.
Poor sleep and waking at 3 a.m.: Here the evidence is a little broader. A meta-analysis of five trials found a small overall improvement in sleep. Effects looked stronger at 600 mg daily for at least eight weeks and in adults diagnosed with insomnia.[4] None of that automatically makes insomnia a menopause symptom. Hot flashes, stress, pain, medication and sleep habits can all drive it. Our magnesium and melatonin sleep guide keeps that bigger picture in view.
Fatigue and brain fog: A later review grouped perimenopause-related studies and reported improvements in fatigue, cognition and quality of life. But most of those studies enrolled people for other reasons, such as stress, obesity or insomnia. They did not test a perimenopause-specific fatigue or brain-fog group.[5] That makes the signal worth noting and easy to misuse.
Libido, fertility or hormones: These are separate claims. Fertility studies often involve men, animals, specific hormone disorders or other reproductive goals. They should not be used to promise that ashwagandha corrects an abnormal fertility result or “fixes” menopause hormones. In the perimenopause trial, estradiol rose and FSH and LH fell versus placebo, but an eight-week hormone change does not prove long-term hormone safety.[1]
What KSM-66 actually is
“Ashwagandha” on a label is not a dose.
KSM-66 is a named, patented aqueous ashwagandha root extract, usually standardized to at least 5% withanolides. The perimenopause trial used 300 mg twice daily, or 600 mg of KSM-66 a day, for eight weeks.[1][5] Evidence from one branded extract cannot be transferred to every root powder, root-and-leaf blend, gummy or capsule with a different standardization.
A practical study-informed range is 300–600 mg daily of a standardized root extract. The 600 mg dose has better representation in sleep research, and some stress studies suggest larger effects around 500–600 mg than lower doses.[3][4] But more is not automatically better. There is no established dose-response curve for perimenopause, and long-term safety is unknown.[6]
Safety: the short list is not optional
NCCIH says ashwagandha may be tolerated for up to three months, but longer-term evidence is insufficient. Reported effects include drowsiness, stomach upset, diarrhea and vomiting. Rare cases of liver injury have also been linked to ashwagandha supplements.[2]
Do not self-start it if you:
- are pregnant or breastfeeding. Major NIH guidance advises avoiding it in both groups.[2]
- have an autoimmune or thyroid disorder. NCCIH does not recommend it for these groups, and thyroid effects have been reported.[2]
- take thyroid hormone, immunosuppressants, sedatives, diabetes or blood-pressure medicines, or anti-seizure drugs. Interaction risk is plausible and has been flagged by NCCIH.[2]
New jaundice, dark urine, severe abdominal pain, marked itching or unusual rash needs prompt medical attention. Stop the supplement and seek advice rather than waiting for the next capsule.
The honest decision
Ashwagandha may be a low-stakes experiment for an adult who wants to explore stress or sleep support and has no contraindication. The most defensible perimenopause trial match is 600 mg daily of standardized KSM-66 for eight weeks, tracked against one symptom you actually want to change.
It is not a replacement for medical care. Bleeding changes, depression, persistent insomnia, thyroid symptoms or symptoms that keep escalating deserve a clinician’s attention. Perimenopause is real. The evidence is promising and thin at the same time.
Sources
- Gopal et al., randomized perimenopause trial
- NCCIH: Ashwagandha—Usefulness and Safety
- Arumugam et al., stress and anxiety systematic review and meta-analysis
- Cheah et al., sleep systematic review and meta-analysis
- Bryson, review of ashwagandha for perimenopausal symptoms
- NIH Office of Dietary Supplements: Ashwagandha